Mindbloom vs. Spravato: 7 Key Differences in Depression Treatment

Mindbloom vs. Spravato at a Glance

Both options are ketamine-based treatments for depression, anxiety, and related conditions that temporarily modulate neural communication. Spravato is a branded esketamine nasal spray requiring in-person visits to a certified clinic with mandatory monitoring.

Mindbloom is a guided virtual ketamine therapy program combining sublingual tablets or subcutaneous injections with clinician oversight, coaching, and integration support. The choice depends on your clinical needs, insurance situation, preference for treatment setting, and how much comprehensive support you want around each session.

Mindbloom vs. Spravato Side-by-Side Comparison Table

What Is Spravato?

Spravato is the brand name for esketamine, a nasal spray derived from the S-enantiomer of ketamine. It received FDA approval in 2019 for adults with treatment-resistant depression, and in 2020 for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.

Under the Spravato REMS program, treatment is administered at a certified healthcare facility with required post-dose monitoring. These facilities must be enrolled in the Spravato REMS (Risk Evaluation and Mitigation Strategy) program to ensure patient safety.

Each session involves self-administering the ketamine nasal spray dosage under direct medical supervision. This is followed by a mandatory two-hour observation period during which your blood pressure is monitored.

A typical Spravato session includes:

• Arrival: Checking in at a REMS-certified clinic.
• Administration: Self-administering the nasal spray under observation.
• Observation: A two-hour mandatory monitoring period.
• Discharge: Arranging transportation home from the clinic, as patients cannot drive themselves home.

Spravato's FDA-approved status means it has undergone randomized controlled trials for its specific indications. However, the in-clinic requirement creates logistical considerations, as patients must arrange transportation and block several hours per visit.

What Is Mindbloom Guided At-Home Ketamine Therapy?

Mindbloom is a guided at-home ketamine therapy provider delivering clinician-supervised treatment for depression, anxiety, PTSD, and related conditions. Ketamine is prescribed off-label by Mindbloom's licensed clinicians for mental health indications.

Off-label prescribing is standard in psychiatry, with a significant share of all psychiatric prescriptions in the United States are written off-label.¹⁰

Each client's program includes clinician consultations, ketamine treatments, one-on-one guide coaching sessions, and unlimited guide messaging. Treatment takes place in your own home, and sessions are supervised remotely through the Mindbloom platform.

A peer treatment monitor is required to be present during every session to ensure safety. Mindbloom's model embeds ketamine therapy within a defined treatment framework that includes clinical oversight, preparation, and integration support.

A Mindbloom program includes:

• Clinician consults: Medical evaluation and ongoing dosage support.
• Ketamine treatments: Sublingual or subcutaneous options for at-home sessions.
• Guide coaching: One-on-one preparation and integration support.
• Community access: Unlimited Group Integration Circles.
• Bloombox: An experiential toolkit with session essentials.
• Mindbloom App: Comprehensive programs with custom soundscapes.

Mindbloom offers both sublingual and subcutaneous administration. This makes it the only at-home provider with a subcutaneous option.

How Do Mindbloom and Spravato Treat Depression?

Both Mindbloom's ketamine and Spravato's esketamine target the glutamate system, which is the brain's primary excitatory neurotransmitter pathway. Conventional antidepressants typically modulate serotonin or norepinephrine over several weeks.

In contrast, ketamine-based treatments temporarily modulate NMDA receptor signaling. This modulation triggers a cascade of downstream effects, including increased AMPA receptor activation and enhanced synaptogenesis.

This process supports neuroplasticity, which is the brain's ability to form and strengthen new neural connections. Many people report noticeable symptom improvement within hours or days of their first session.

The mechanism cascade includes:

• NMDA modulation: Temporarily adjusts signaling between brain regions.
• Glutamate surge: Increases availability of the excitatory neurotransmitter.
• AMPA activation: Stimulates receptors that promote neural growth.
• Synaptogenesis: Helps form new connections between neurons.

More durable and cumulative benefits typically develop over a series of sessions. While racemic ketamine (used by Mindbloom) and esketamine (used in Spravato) have somewhat different receptor binding profiles, the shared mechanism explains why both approaches can produce rapid antidepressant effects.

How Are Mindbloom and Spravato Administered?

Spravato is administered as a nasal spray in a certified clinic. Mindbloom delivers ketamine at home via sublingual tablets or subcutaneous injection.

The administration method affects onset, ketamine bioavailability, and the logistical demands on the patient. Spravato requires repeated clinic visits, whereas Mindbloom's at-home model removes travel friction while maintaining clinical oversight.

Administration methods include:

• Spravato administration: You arrive at a REMS-certified clinic, self-administer the nasal spray under observation, and remain for a two-hour monitoring period.
• Mindbloom sublingual tablets: You hold small tablets between your cheeks and gums for seven minutes, with the ketamine sublingual dose taking effect within 10–15 minutes.
• Mindbloom subcutaneous injection: Mindbloom injections are administered via a small insulin-type needle into the abdomen, with effects beginning in approximately five minutes.

Mindbloom's subcutaneous option offers higher bioavailability and more consistent session intensity compared to sublingual tablets. Both Mindbloom methods require a peer treatment monitor to be present in your home.

Who Is Eligible for Mindbloom vs. Spravato?

Both Mindbloom and Spravato require clinical evaluation before treatment begins, but their eligibility criteria differ. Spravato's eligibility is narrower by regulatory design, while Mindbloom evaluates a broader range of conditions.

Spravato is FDA-approved specifically for adults with treatment-resistant depression. This is defined as an inadequate response to at least two oral antidepressants in the current depressive episode.

Spravato is also approved for major depressive disorder with acute suicidal ideation. Contraindications include aneurysmal vascular disease and a history of intracerebral hemorrhage.

Mindbloom clinicians evaluate candidates for depression, anxiety, PTSD, and related conditions. A qualifying diagnosis is required, but prior antidepressant failure is not a prerequisite for treatment.

While ketamine is not FDA approved for PTSD, licensed clinicians frequently prescribe it off-label for PTSD based on clinical evidence and patient needs. Ketamine therapy may not be appropriate for individuals with uncontrolled hypertension, active psychosis, or certain cardiac conditions, which the clinician evaluates during screening.

Mindbloom vs. Spravato Effectiveness and Published Research

Direct comparisons across treatment modalities should be interpreted with caution due to differences in study design, patient populations, and outcome measures. Both options have published evidence supporting their use, though they draw from different types of studies.

Spravato's FDA approval was based on multiple randomized controlled trials that specifically enrolled patients with treatment-resistant depression. In phase 3 trials, Spravato plus an oral antidepressant demonstrated statistically significant improvement in depression scores compared to placebo nasal spray plus an oral antidepressant, with response rates varying across studies.

Building on decades of clinical research, Mindbloom has published two of the largest peer-reviewed, real-world outcomes studies of at-home ketamine therapy. These studies were published in the Journal of Affective Disorders and conducted on Mindbloom clients using the Mindbloom protocol.^1,2

Mindbloom's published outcomes data shows:

• Depression improvement: In a peer-reviewed study of 11,441 patients, 89% of clients reported improvement in their symptoms, with a 56.4% response rate.²
• Anxiety improvement: In the same study, 89% of participants reported improvement in their symptoms, with a 56.1% response rate.²
• PTSD improvement: In a real-world analysis of 374 PTSD program completers, 92.2% reported symptom improvement, with a 79.7% response rate.³

Mindbloom's reported depression response rate (56.4%)² is comparable to or modestly exceeds those reported in selected IV ketamine studies.⁴ Mindbloom's reported anxiety response rate (56.1%)² exceeds response rates reported in selected SSRI trials.⁶

Additionally, Mindbloom's reported PTSD response rate (79.7%)³ exceeds response rates reported in randomized trials of prolonged exposure therapy.⁷ Individual results may vary, but reading Mindbloom reviews often highlights these rapid shifts in perspective.

Mindbloom vs. Spravato Side Effects and Safety

Both Mindbloom and Spravato can produce temporary side effects related to their shared pharmacology. Common acute effects can include dissociation, sedation, dizziness, nausea, and temporary increases in blood pressure; dissociation is a known effect of ketamine that is prepared for and monitored during treatment.

Ketamine can cause a temporary increase in blood pressure and heart rate during the session. This occurs because the medication has sympathomimetic properties, meaning it temporarily stimulates your cardiovascular system.

Individuals with uncontrolled hypertension may not be appropriate candidates, which is why cardiovascular screening is a mandatory part of the intake process. Spravato manages this through in-person monitoring for two hours post-dose, measuring blood pressure at specific intervals.

Dissociation refers to a sense of detachment from your body or environment. It is a known pharmacological effect of ketamine that can feel unfamiliar or intense, but it is not inherently dangerous.

Dissociative effects are generally limited to the dosing window, and preparation, a peer treatment monitor, and clinician-guided integration are used to help patients stay oriented and process the experience. Mindbloom manages safety through its comprehensive safety protocol, including rigorous medical screening, the peer treatment monitor requirement, and ongoing clinician oversight.

Dependence refers to a physical or psychological reliance on a substance. While ketamine is a Schedule III medication with dependence potential, this risk is primarily documented in chronic, unsupervised recreational use patterns involving frequent, high doses.¹¹

Mindbloom mitigates this risk through strict clinical screening, controlled dispensing of exact therapeutic doses, and ongoing clinician oversight. Mindbloom's published safety data shows that side effects occur at approximately 4–5% of sessions, serious adverse events at fewer than 0.1%, and discontinuation at 0.4%.²

Mindbloom vs. Spravato Cost, Insurance, and Access

Spravato and Mindbloom operate under fundamentally different payment and access models. The best fit depends on your insurance situation, proximity to a certified clinic, and how you weigh direct cost against time and convenience.

Cost and Insurance

Spravato is more commonly covered by commercial insurance and Medicare Part B than generic ketamine, which can meaningfully reduce out-of-pocket costs for patients who qualify. Prior authorization is typically required, and copays vary by plan, but for patients with eligible coverage, Spravato may be the more affordable option on a per-session basis.

Mindbloom is typically paid out of pocket and is not covered by most insurance plans directly. All programs are eligible for HSA and FSA funds, and pricing is transparent and structured in monthly installments:

• 6-Session Program: $1,290 total, paid as $430 per month for 3 months.
• 12-Session Program: $2,220 total, paid as $370 per month for 6 months.
• 18-Session Program: $2,970 total, paid as $330 per month for 9 months.

Convenience and Access

Spravato must be administered at a REMS-certified clinic, and availability depends on proximity to a participating facility. During the induction phase, sessions are typically scheduled twice weekly for four weeks, followed by weekly or biweekly maintenance. Each visit requires travel to the clinic, a mandatory two-hour post-dose observation period, and arranged transportation home, as patients cannot drive after treatment.

Mindbloom's at-home model eliminates clinic scheduling, travel, and the need for a driver. Sessions take place in your own home on your own schedule, supervised remotely through the Mindbloom platform. A peer treatment monitor is required to be present, but treatment can be scheduled around your daily life rather than around clinic availability.

Mindbloom vs. Spravato Care Model and Support

Ketamine-based treatment can be delivered as medication alone or as part of a comprehensive therapeutic program. The distinction matters for long-term outcomes and the post-session transition.

Spravato's care model centers on medication administration and observation. Treatment is administered by healthcare staff at a certified clinic, with clinical interaction focusing on the dosing session itself.

Ongoing psychiatric care, such as talk therapy or daily medication management, typically occurs separately through the patient's existing providers. Spravato does not include built-in coaching or integration support as part of its standard offering.

Mindbloom provides a protocol-driven program where ketamine is one component of a broader therapeutic framework. Each program includes clinician consultations, one-on-one guide coaching sessions for preparation, and unlimited Group Integration Circles.

Integration is the process of making meaning from the ketamine experience and applying insights to daily life. In Mindbloom's model, integration is a built-in component designed to support durable change, rather than an optional add-on.

Which Option Is Right for You — Mindbloom or Spravato?

Both options represent clinically grounded approaches to ketamine-based treatment. This self-assessment can help you evaluate your own needs against what each option provides.

Spravato may be a better fit if you:

• Have been diagnosed with treatment-resistant depression (inadequate response to two or more antidepressants).
• Prefer or require in-person medical supervision during every session.
• Have insurance coverage that includes Spravato with manageable copays.
• Have access to a REMS-certified treatment center near you.
• Want an FDA-approved medication for your specific indication.

Mindbloom may be a better fit if you:

• Are seeking treatment for depression, anxiety, PTSD, burnout, grief, or related conditions — whether or not prior medications have been tried.
• Prefer the comfort and convenience of at-home treatment.
• Want a comprehensive program with coaching, integration, and community support built in.
• Are paying out of pocket and want a more affordable per-session cost than in-clinic options.
• Want the option of subcutaneous administration for more consistent bioavailability.

The right choice depends on your diagnosis, insurance situation, preference for treatment setting, and how much support you want surrounding each session. A conversation with a licensed clinician can help clarify which path aligns with your needs.

Disclaimer and Safety Information

IMPORTANT SAFETY INFORMATIONKetamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

‍OFF-LABEL USE DISCLOSUREKetamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.